In March 2013, the U.S. Food and Drug Administration (FDA) announced the approval of the first retinal implant device. The device, Argus II, was designed to replicate some of the retina’s functions for patients suffering from retinitis pigmentosa. At the America Academy of Ophthalmology’s annual meeting last fall, research presented revealed Argus II as having strong potential in aiding those suffering from the genetic disease to better recognize common items by enhancing their outlines.
Researchers studied eight patients wearing the retinal prosthesis, asking them to identify white or metallic objects placed in front of a dark background. They were then asked to identify the same items a second time with enhanced outlines. This test was conducted three times per patient – once with the retinal prosthesis in standard mode, once in scrambled mode as a positive control and then again with the device turned off to serve as a negative control.
The results of the identification of “solid objects” increased from 12.5 percent correct with the device turned off to 32.8 percent when the device was turned on. 26.2 percent were identified correctly when the device was placed in scrambled mode. When the items’ outlines were enhanced, 9.4 percent …![]()